Method of administration of paclitaxel-plasma protein formulation
US6569459B2 · kind B2 · utility
1Cited by
15References
20Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 10, 2001 |
| Grant date | May 27, 2003 |
| Priority date | — |
| Expiry date | Apr 10, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/0019
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides for a method for treating human or animal patients with paclitaxel formulation, the method comprising an intratumoral dose of a paclitaxel formulation and an intravenous dose of paclitaxel. The intravenous dose occurs about 1 to about 7 days after the intratumoral dose. The paclitaxel formulation may typically be either a paclitaxel/HSA formulation or paclitaxel/&ggr;-globulin formulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.